BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36580798)

  • 1. Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia.
    Zhang X; Chen D; Zhao X; Wang C; He Y; Chen Y; Wang J; Shen D
    Pathol Res Pract; 2023 Jan; 241():154278. PubMed ID: 36580798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance of molecular classification in fertility-sparing treatment of endometrial carcinoma and atypical endometrial hyperplasia].
    Wang YQ; Kang N; Li LW; Wang ZQ; Zhou R; Shen DH; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):692-700. PubMed ID: 36177581
    [No Abstract]   [Full Text] [Related]  

  • 3. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
    Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
    Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma.
    Chapel DB; Patil SA; Plagov A; Puranik R; Mendybaeva A; Steinhardt G; Wanjari P; Lastra RR; Kadri S; Segal JP; Ritterhouse LL
    Mod Pathol; 2019 Oct; 32(10):1508-1520. PubMed ID: 31186530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia.
    Lv X; Guo L; Wang C
    J Gynecol Oncol; 2024 May; 35(3):e27. PubMed ID: 38216133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fertility-preserving treatment outcomes in endometrial cancer and atypical hyperplasia patients with different molecular profiles].
    Shao WY; Dong YT; Lyu QY; Liao JB; Xue Y; Chen XJ
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):742-754. PubMed ID: 37849255
    [No Abstract]   [Full Text] [Related]  

  • 7. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?
    Lucas E; Chen H; Molberg K; Castrillon DH; Rivera Colon G; Li L; Hinson S; Thibodeaux J; Lea J; Miller DS; Zheng W
    Int J Gynecol Pathol; 2019 Nov; 38(6):533-542. PubMed ID: 30383610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia.
    Xue Y; Dong Y; Lou Y; Lv Q; Shan W; Wang C; Chen X
    J Gynecol Oncol; 2023 Jul; 34(4):e53. PubMed ID: 36929579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial Cancer Following Levonorgestrel-Releasing Intrauterine System Insertion in Young Women with Atypical Hyperplasia: Two Case Reports and Literature Review.
    Peng H; Jiang J; Li X
    Reprod Sci; 2022 Nov; 29(11):3278-3284. PubMed ID: 35641856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
    Gong Q; Chen X; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review.
    Murakami I; Machida H; Morisada T; Terao Y; Tabata T; Mikami M; Hirashima Y; Kobayashi Y; Baba T; Nagase S
    J Gynecol Oncol; 2023 Jul; 34(4):e49. PubMed ID: 36929578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
    Yang B; Xu Y; Zhu Q; Xie L; Shan W; Ning C; Xie B; Shi Y; Luo X; Zhang H; Chen X
    Gynecol Oncol; 2019 Apr; 153(1):55-62. PubMed ID: 30674421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
    Acosta-Torres S; Murdock T; Matsuno R; Beavis AL; Stone RL; Wethington SL; Levinson K; Grumbine F; Ferriss JS; Tanner EJ; Fader AN
    Gynecol Oncol; 2020 May; 157(2):348-356. PubMed ID: 32085863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: Outcomes from an institutional series.
    Falcone F; Normanno N; Losito NS; Scognamiglio G; Esposito Abate R; Chicchinelli N; Casella G; Laurelli G; Scaffa C; Greggi S
    Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():220-225. PubMed ID: 31326637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management.
    Abdulfatah E; Wakeling E; Sakr S; Al-Obaidy K; Bandyopadhyay S; Morris R; Feldman G; Ali-Fehmi R
    Gynecol Oncol; 2019 Sep; 154(3):467-474. PubMed ID: 31248668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
    Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
    Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
    Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
    J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology].
    Lax S
    Pathologe; 2011 Nov; 32 Suppl 2():255-64. PubMed ID: 22033684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA-seq and ATAC-seq analysis of CD163
    Wang L; Lv Q; Wu P; Luo S; Liu S; Chen X; Luo X
    Cancer Med; 2023 Mar; 12(5):5964-5978. PubMed ID: 36373483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
    Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
    Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.